Independent Advisor Alliance lessened its position in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 52.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 17,474 shares of the medical equipment provider’s stock after selling 19,486 shares during the quarter. Independent Advisor Alliance’s holdings in Boston Scientific were worth $1,666,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. Atlantic Union Bankshares Corp increased its holdings in Boston Scientific by 1,962.1% during the 4th quarter. Atlantic Union Bankshares Corp now owns 598 shares of the medical equipment provider’s stock valued at $57,000 after acquiring an additional 569 shares in the last quarter. World Investment Advisors lifted its holdings in shares of Boston Scientific by 2.2% in the fourth quarter. World Investment Advisors now owns 19,365 shares of the medical equipment provider’s stock valued at $1,777,000 after purchasing an additional 411 shares in the last quarter. Rock Point Advisors LLC acquired a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $2,209,000. Meridian Wealth Management LLC increased its stake in shares of Boston Scientific by 162.3% during the 4th quarter. Meridian Wealth Management LLC now owns 14,553 shares of the medical equipment provider’s stock worth $1,388,000 after purchasing an additional 9,005 shares in the last quarter. Finally, Strategic Planning Group LLC increased its stake in shares of Boston Scientific by 18.6% during the 4th quarter. Strategic Planning Group LLC now owns 53,388 shares of the medical equipment provider’s stock worth $5,091,000 after purchasing an additional 8,358 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of equities research analysts recently issued reports on the company. TD Cowen reduced their target price on Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, February 2nd. Weiss Ratings downgraded Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday. Stifel Nicolaus reduced their price objective on Boston Scientific from $90.00 to $85.00 and set a “buy” rating on the stock in a research report on Tuesday, April 21st. UBS Group decreased their price objective on Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a research note on Tuesday, March 17th. Finally, Citigroup dropped their price objective on Boston Scientific from $94.00 to $87.00 and set a “buy” rating for the company in a research report on Tuesday, April 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and an average price target of $93.91.
Boston Scientific Trading Down 1.7%
Shares of BSX opened at $52.67 on Friday. Boston Scientific Corporation has a fifty-two week low of $52.52 and a fifty-two week high of $109.50. The company has a market capitalization of $78.27 billion, a PE ratio of 22.04, a price-to-earnings-growth ratio of 0.98 and a beta of 0.62. The stock has a fifty day moving average of $63.40 and a two-hundred day moving average of $81.79. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90.
Boston Scientific (NYSE:BSX – Get Free Report) last posted its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business’s revenue was up 11.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, analysts forecast that Boston Scientific Corporation will post 3.38 EPS for the current year.
Boston Scientific Profile
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.
Featured Articles
- Five stocks we like better than Boston Scientific
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
